Introduction {#s1}
============

Due to its central role in signal transduction, extracellular-signal regulated kinase (ERK) has been the subject of intense study for over three decades ([@bib49]; [@bib50]); this research has elucidated many of the key mechanisms of ERK regulation. This pathway is utilized by a host of different extracellular cues to regulate cellular processes such as proliferation, differentiation, and survival ([@bib22]; [@bib45]). However, studies have shown that ERK is also critically involved in regulating many other cellular processes, such as cell migration ([@bib36]; [@bib35]), cell cycle progression ([@bib43]; [@bib6]), autophagy ([@bib15]; [@bib19]), metabolism ([@bib52]; [@bib18]), insulin secretion ([@bib42]), or even apoptosis ([@bib26]; [@bib4]). The variety of processes induced through the ERK pathway presents a conundrum: how do extracellular cues specifically regulate the ERK pathway to induce the proper cellular response?

The canonical mode of regulation is activation by phosphorylation at the end of a kinase cascade. ERK is phosphorylated by the protein kinase mitogen-activated protein kinase kinase (MEK), which is first activated by the protein kinase Raf. Raf kinases are activated through the GTPase Ras, which is activated downstream of extracellular signals such as Epidermal Growth Factor (EGF) ([@bib45]; [@bib5]). However, because ERK is activated by phosphorylation by a host of divergent extracellular signals, more complex modes of regulation must exist in order to direct ERK activity toward appropriate responses.

Previous studies have shown that different extracellular signals induce distinct temporal patterns of ERK activation to encode specific signaling information ([@bib38]; [@bib13]; [@bib48]). For example, in model cell lines such as PC12 or MCF7, EGF treatment leads to transient ERK phosphorylation and cell proliferation, whereas alternate extracellular signals such as Nerve Growth Factor (NGF) or heregulin, respectively, induces sustained ERK phosphorylation and cell differentiation. In the case of PC12 cells, the latter includes neurite formation and an enlarged cell body, modeling differentiated neurons. However, previous studies primarily used immunoblotting techniques to monitor ERK activation dynamics. While this technique has yielded crucial information, it is ultimately limited in its spatiotemporal resolution and unable to resolve single-cell behavior or differential dynamics between subcellular compartments.

ERK substrates have been identified in many subcellular compartments including at the Golgi Apparatus ([@bib16]; [@bib51]; [@bib61]), at the mitochondrial membrane ([@bib57]; [@bib39]), and near the plasma membrane ([@bib36]; [@bib35]). However, studies investigating the spatial regulation of ERK have primarily focused on understanding its activation and role in shuttling between the nucleus and cytoplasm, leaving the regulation and function of ERK in other subcellular compartments relatively unexplored. We hypothesize that spatial compartmentalization of ERK activity is required for signaling specificity in order for signals such as EGF to regulate different functional responses via distinct compartmentalized ERK activity. To test our hypothesis, we utilized genetically encoded molecular tools to visualize and perturb the activities of specific subcellular pools of endogenous ERK. Using this native biochemistry approach ([@bib47]; [@bib34]; [@bib28]), we discovered that ERK activity associated with the plasma membrane exhibits distinct temporal dynamics in contrast to cytoplasmic and nuclear pools of ERK. We further dissected the mechanism of this distinct regulation and discovered that plasma membrane ERK activity is required for regulating Rac1 and controlling actin protrusion dynamics.

Results {#s2}
=======

EGF-induced ERK activity is transient in the cytoplasm but sustained near the plasma membrane {#s2-1}
---------------------------------------------------------------------------------------------

While previous studies revealed that the temporal dynamics of ERK activation play a pivotal role in promoting specific cellular responses to extracellular stimuli ([@bib38]; [@bib13]; [@bib12]), studies on the spatial activation of ERK in signal transduction has been mostly focused on its translocation to the nucleus despite the fact that ERK has hundreds of substrates in other subcellular compartments ([@bib65]). For example, ERK has several known substrates near the plasma membrane, including Focal Adhesion Kinase ([@bib17]) and the actin-effector Wiskott--Aldrich Syndrome Protein (WASP) ([@bib35]). Thus, we sought to determine whether a single extracellular signal could induce different activity dynamics of spatially distinct pools of ERK to promote functional cellular processes. To address this question, we developed a new toolset of genetically encoded, spatially localized fluorescent biosensors based on the ERK Kinase Activity Reporter (EKAR) ([@bib12]; [@bib24]), an engineered fluorescent ERK substrate that will exhibit different FRET properties in response to phosphorylation by ERK. These biosensors consist of two fluorescent proteins flanking a WW phosphopeptide-binding domain, a linker region, and an ERK-specific substrate domain ([Figure 1A](#fig1){ref-type="fig"}). Upon phosphorylation of the substrate sequence by ERK, the WW phosphopeptide-binding domain interacts with the phosphorylated substrate sequence, bringing the two fluorescent proteins into close proximity, thereby increasing FRET ([@bib54]). Thus, by expressing the biosensor within cells, one can monitor ERK activity in living cells in real-time by exciting the donor fluorescent protein and measuring the changes in the ratio of acceptor to donor fluorescence, yellow over cyan (Y/C), which is often reported as a percent increase over basal signal. Previous versions of EKAR include EKAR-EV, EKAR2G, and EKAR3 ([@bib24]; [@bib9]; [@bib53]). While each of these biosensors has improved upon past biosensors, each of their reported average response to EGF is below 50%, which limits their utility to be used when targeted to specific subcellular locations. In seeking to develop a new EKAR biosensor with sufficient dynamic range in order to maximize signal when the biosensor is restrained to specific locations, we found that switching the positions of the fluorescent proteins within the EKAR-EV biosensor such that Ypet was positioned C-terminally and ECFP was positioned N-terminally ([Figure 1A](#fig1){ref-type="fig"}) yielded a biosensor that generated an 74.5 ± 2.3% increase in the Y/C emission ratio in PC-12 cells (n = 83) ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). We also directly compared EKAR4 to EKAR2G1 and EKAR-EV in HEK-293 cells and observed a significantly improved dynamic range from the previous biosensors ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). We reasoned that this enhanced EKAR, which we have termed EKAR4, can then be targeted to specific subcellular locations, such as the cytoplasm, plasma membrane, or nucleus, to enable reliable tracking of ERK temporal dynamics in these specific locations. Thus, we used a Nuclear export signal (NES) to create a cytosolic targeted EKAR4 (cytoEKAR4), a nuclear localization sequence (NLS) to create a nuclear targeted EKAR4 (nuclearEKAR4), and the hypervariable region of KRas including a polylysine and CAAX box sequence to create a plasma membrane-localized EKAR4 (pmEKAR4), each of which displayed correct localization ([@bib11]; [Figure 1B](#fig1){ref-type="fig"}, [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}).

![Targeted, FRET-based ERK biosensors reveal differential temporal dynamics of subcellular ERK activity.\
(**A**) Domain structure of improved ERK-kinase activity reporter (EKAR4). EKAR4 has two fluorescent proteins (ECFP and YPet) on N- and C-termini, respectively, with an ERK-specific substrate sequence, a phosphopeptide-binding domain (WW), and the EV-linker developed by [@bib24] (**B**) Pseudocolor images representing the yellow over cyan (Y/C) emission ratio of cytosolic EKAR4 (cytoEKAR4) (top) versus plasma membrane-targeted EKAR4 (bottom) after EGF treatment at time 0. Warmer colors indicate higher Y/C emission ratio, scale bar = 10 µm. (**C**) Spatiotemporal dynamics of EGF-induced ERK activity in the cytosol. Cytoplasmic ERK activity was monitored using cytoEKAR4 in cells treated with 100 ng/µl EGF (black dotted line, n = 83) or pretreated with 10 µM SCH772984 (ERK inhibitor) 20 min before EGF (blue, triangles, n = 19). Each trace is a combined average of all cells. (**D**) Spatiotemporal dynamics of EGF-induced ERK activity at the plasma membrane. Plasma membrane localized ERK activity was monitored using the plasma membrane targeted EKAR4 (pmEKAR4) in cells treated with 100 ng/µl EGF (black dotted line, n = 71) or pretreated with 10 µM SCH772984 (ERK inhibitor) 20 min before EGF (blue, triangles, n = 24). Each trace is a combined average of all cells (see [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}, B for traces of all cells for C and D; Error bars represent 95% CI.) E) Activity persistence differences of ERK response to EGF between the cytoplasm and plasma membrane. Using the SAM40 metric ([Equation 1](#equ1){ref-type="disp-formula"}), the transient versus sustained nature of ERK response to EGF at the cytoplasm (n = 83) and plasma membrane (n = 71) was quantified. (\*\*\*\*p\<0.0001 using one-way ANOVA multiple comparisons, see [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"} for comparison to nuclear ERK activity.) See also [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}, [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}.\
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Live-cell imaging experiments revealed striking differences in the temporal patterns of ERK activity at different subcellular locations. EGF induced transient ERK activity in the cytosol and nucleus ([Figure 1C](#fig1){ref-type="fig"}, [Figure 1---figure supplement 3B,C](#fig1s3){ref-type="fig"}), consistent with previous reports. In contrast, EGF-stimulated pmEKAR4 response was much more sustained at the plasma membrane ([Figure 1D](#fig1){ref-type="fig"}, [Figure 1---figure supplement 3A](#fig1s3){ref-type="fig"}), compared to cytosol and nucleus. We developed a metric to quantitate the relative temporal dynamics between conditions ([Equation 1](#equ1){ref-type="disp-formula"}), which we refer to as Sustained Activity Metric at 40 min post-treatment (SAM40), where *R* represents the normalized emission ratio at the indicated condition in subscript.$$\frac{R_{40} - R_{0}}{R_{max} - R_{0}}$$

An advantage of this metric is that it presents the residual signal at 40 min from the maximum signal after treatment. Using this metric, we were able to determine that EKAR4 response at the plasma membrane was indeed statistically different from the cytoplasmic and nuclear ERK responses ([Figure 1E](#fig1){ref-type="fig"}, [Figure 1---figure supplement 3D](#fig1s3){ref-type="fig"}, [Figure 1---figure supplement 4](#fig1s4){ref-type="fig"}). Interestingly, we also found that the kinetics of ERK activity accumulation were slower at the plasma membrane versus cytosol and nucleus ([Figure 1---figure supplement 3F](#fig1s3){ref-type="fig"}), using the time to ½ maximum responses as a proxy ([@bib3]; [@bib46]; [@bib62]), which is dependent on both ERK and phosphatase activity.

We also compared the EKAR4 responses to conventional methods of evaluating ERK by treating PC-12 cells with EGF and harvesting cells before treatment (control), at 7.5 min, 15 min, 30 min, and 40 min post-EGF treatment ([Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}) and subjected cell lysates to immunoblot for phosphorylated and total ERK. In this time course, we observe a dramatic increase in phosphorylated ERK 7.5 min after EGF treatment, followed by a dramatic decrease by 15 min. It is interesting that after 15 min we see a slight increase in phospho-ERK at the 30- and 40 min time points. The activation profile is broadly similar to the EKAR response. The decrease in phospho-ERK is faster than the EKAR signal, likely because the EKAR biosensor signal dynamics is dependent on both ERK and phosphatase activities.

To test if the sustained response at the plasma membrane requires continuously active ERK at the plasma membrane, we treated the cells with a membrane permeable ERK inhibitor SCH772984 ([@bib37]) and examined the pmEKAR4 responses. We found that addition of 10 µM SCH772984, but not of DMSO ([Figure 2---figure supplement 1C,D](#fig2s1){ref-type="fig"}), either at 10 min after EGF stimulation ([Figure 2A](#fig2){ref-type="fig"} blue curve) or at 40 min post-stimulation ([Figure 2A](#fig2){ref-type="fig"} orange curve) resulted in an immediate change in the slope of pmEKAR4 signal, indicating that ERK was still actively phosphorylating pmEKAR4 at these time points ([Figure 2A](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Interestingly, inhibitor addition at these different time points appears to exhibit different slopes of decay, which we surmise to be due to changing phosphatase activities between these time points. Furthermore, addition of U0126, an inhibitor of the upstream kinase MEK, at 10 min or 40 min post EGF also led to decreases in the slope of pmEKAR4 signal ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}), indicating MEK was also active.

![Sustained ERK activity at the plasma membrane is required for observed pmEKAR4 signal.\
(**A**) PC12 cells treated with the ERK inhibitor SCH772984 (10 µM) after EGF treatment at 10 min (n = 8) or 40 min (n = 8) post-EGF resulted in an immediate change in the slope of pmEKAR4 signal. (**B**) PC12 cells were harvested at select time points after EGF treatment and the lysates underwent subcellular fractionation, which is verified in [Figure 2---figure supplement 1E](#fig2s1){ref-type="fig"}. After successful fractionation between the plasma membrane and other cellular components, a western blot against the phosphorylated and total form of ERK1/2 indicates that the levels of phospho-ERK remain relatively consistent up to 40 min after EGF treatment. Quantitation from five independent replicates is shown in panel C. (\*p\<0.05, \*\*\*\*p\<0.0001, calculated using one-way ANOVA with multiple comparisons.) See also [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}.\
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To further validate the ERK activity dynamics at different subcellular compartments, we performed biochemical subcellular fractionation ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}) to separate and quantitate ERK phosphorylation at the plasma membrane and cytoplasm of PC12 cells to assess the temporal dynamics of phosphorylated ERK. ERK was phosphorylated transiently in the cytoplasm and ERK associated with the plasma membrane was, on average, equally phosphorylated between the 15- and 40 min time points ([Figure 2B](#fig2){ref-type="fig"}, quantitated from five independent replicates in C), indicating the presence of a continuously phosphorylated pool of ERK at the plasma membrane. In conclusion, these data indicate that ERK activity associated with the membrane is sustained in contrast to the transient response in the cytoplasm and nucleus, and thus differentially regulated between these subcellular compartments.

Rap1 GTPase significantly contributes to plasma membrane ERK activity {#s2-2}
---------------------------------------------------------------------

The unique temporal pattern of ERK activity at the plasma membrane prompted us to determine whether plasma membrane ERK activity is distinctly regulated. The classical pathway of ERK activation is through the Ras family of GTPases, including K-ras, H-ras, and N-Ras ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). However, it has been shown that Rap1, a GTPase in the Ras family, can in some cases specifically interact with B-Raf and lead to sustained ERK activity under certain conditions ([@bib56]; [@bib27]; [@bib66]). For example, NGF-induced sustained ERK activation in PC12 cells is mediated through Rap1 ([@bib66]). More recent reports suggest that while Ras activates a rapid and intense ERK response, Rap1 induces a slow and steady ERK response ([@bib27]), mimicking the observed kinetic difference between responses of pmEKAR4 and cytoEKAR4. In addition, Wang et al. showed that in order for Rap1 to activate the ERK pathway, Rap1 needs to be localized near the plasma membrane ([@bib63]). These observations led us to hypothesize that a plasma membrane-associated pool of active Rap1 exists to regulate plasma membrane ERK activity.

The classical way to measure GTPase activation involves affinity capture of the active GTPase and subsequent immunodetection for the presence of the GTPase in the precipitated fraction. We reasoned that because the plasma membrane-associated pool of Rap1 may be relatively small compared to the cytosolic and perinuclear pools of Rap1, this classical method involving affinity-capture would not be suitable to test whether EGF induces Rap1 ([@bib63]; [@bib41]). Recently, O'Shaughnessy et al. reported novel dual-chain biosensors for both of the isoforms of Rap1, Rap1A and Rap1B ([@bib40]). In these biosensors known as Rap1A/B-FLARE, either Rap1A or Rap1B is fused to the donor fluorophore, mCerulean3, on its N-terminus and the Rap1-binding domain (RBD) from RalGDS is fused to the acceptor fluorophore Ypet. Rap1 activation leads to intermolecular binding between Rap1 and RBD, thereby increasing FRET. Using these biosensors in PC12 cells (see [Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"} for diagram of pathway including inhibitors and biosensors utilized throughout this study), we observed that EGF consistently induced increases in Y/C emission ratios, indicating activation of both Rap1A (25.4 ± 4.7%, n = 11) and Rap1B (26 ± 3.4%, n = 8); this effect was completely abrogated by either co-expression of the Rap1-specific GTPase-activating protein Rap1GAP, which selectively inactivates Rap1 by inducing the hydrolysis of the bound GTP to GDP ([Figure 3A,B](#fig3){ref-type="fig"}, red curves, [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}; [@bib2]; [@bib7]), or by GGTI-298, a geranylgeranyltransferase I inhibitor that has been used to inhibit the processing, and thus action, of Rap1 ([Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}; [@bib8]; [@bib21]; [@bib33]). We also tested Rap1 activation near the plasma membrane by using Total Internal Reflection Microscopy (TIRF) to monitor the translocation to the plasma membrane of a FP-tagged effector molecule that binds to GTP bound form of Rap1. For this assay, we utilized the RBD from diffusible, FP-tagged RalGDS ([@bib63]). We also co-expressed a membrane-targeted variant of RFP, mCherry, in PC12 cells in order to aid in finding cells in TIRF microscopy and to control for changes in fluorescence intensity due to cell spreading and/or movement. In these cells, EGF induced an average maximum response of 64.8 ± 11% (n = 11) increase in ratio of EGFP to mCherry at the basal membrane, while control cells expressing EGFP showed no changes in EGFP fluorescence intensity at the membrane ([Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}). Furthermore, co-expression of Rap1GAP abolished the translocation of the RBD, further confirming the specificity of the response.

![Rap1 GTPase regulates EGF-induced ERK activity at the plasma membrane.\
Cells expressing either (**A**) diffusible Rap1A FLARE (n = 11) or (**B**) diffusible Rap1B FLARE (n = 9) were treated with EGF at time 0, increase in yellow over cyan (Y/C) emission ratio indicates Rap1 activation. The observed increases in ratio are abrogated by co-expression of the Rap1-specific GAP Rap1GAP (red curves, n = 14, n = 15, respectively). (**C, E**) Rap1GAP expression significantly dampened pmEKAR4 response (n = 40). (**D, F**) Rap1GAP expression had no significant effect on cytosolic ERK activity (n = 40). (\*\*\*\*p\<0.0001, n.s. = not significant, calculated using student's t-test with Welch's correction) See also [Figure 3---figure supplements 1](#fig3s1){ref-type="fig"}--[6](#fig3s6){ref-type="fig"}.\
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Having verified EGF induces Rap1 activation near the plasma membrane, we investigated how abrogation of Rap1 would affect plasma membrane localized ERK activity. We used several different approaches to inhibit Rap1. First, Rap1GAP-mediated inhibition of both Rap1A and Rap1B led to a dramatic dampening of EGF-induced ERK activity near the plasma membrane ([Figure 3C,E](#fig3){ref-type="fig"}, and [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). However, Rap1GAP had no effect on cytosolic ERK activity ([Figure 3D,F](#fig3){ref-type="fig"}), indicating that the effect of Rap1GAP is plasma membrane specific. Secondly, we expressed Rap1A and Rap1B dominant-negative isoforms (Rap1A N17 and Rap1B N17) ([@bib30]). While Rap1A N17 was not able to inhibit Rap1A activation, Rap1B N17 dramatically decreased Rap1B activation ([Figure 3---figure supplement 5B,D](#fig3s5){ref-type="fig"}) and led to a similar effect on pmEKAR response as Rap1GAP expression ([Figure 3---figure supplement 5F,G](#fig3s5){ref-type="fig"}). In addition, acute Rap1A inhibition by GGTI-298 also resulted in a drastically decreased pmEKAR4 response ([Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}). These data indicate that Rap1 is critically involved in regulating plasma membrane ERK activity. However, we note that Rap1 inhibition does not completely abrogate plasma membrane ERK response. We thus used HRas-N17, a dominant negative form of H-Ras that inhibits all Ras isoforms ([@bib32]), to probe how inhibition of Ras affects both cytosolic and plasma membrane localized ERK. We found that cytosolic ERK activity was completely abolished ([Figure 3---figure supplement 6A,B](#fig3s6){ref-type="fig"}). We also found that plasma membrane localized ERK activity was altered, but not abolished like the cytoEKAR4 response. Instead of an initial peak response approximately 10 min after EGF followed by a slow decay, we observed a slowly increasing plasma membrane ERK response ([Figure 3---figure supplement 6C,D](#fig3s6){ref-type="fig"}). Interestingly, the amplitude of pmEKAR4 at 40 min was not different between HRas-N17 expressing cells and control cells, indicating that Rap1, not Ras, is responsible for plasma membrane ERK activity at later time points. This mechanism is notably different from the canonical Ras-mediated activation of ERK, which appears to regulate the cytoplasmic and nuclear ERK activities.

Plasma membrane ERK activity regulates cellular morphology and EGF-induced protrusion dynamics {#s2-3}
----------------------------------------------------------------------------------------------

After identifying a distinct pool of ERK with different temporal dynamics and pathway of activation than cytosolic or nuclear pools of ERK, we sought to identify the function of this pool of ERK near the membrane. We utilized an ERK monobody binder (EMBer) ([@bib31]) that interacts with ERK and inhibits its activity but does not interact with JNK or p38, kinases from the same family as ERK. Using plasma membrane targeted EMBer tagged with mCherry (pmEMBer), we observed a significantly reduced ERK activity near the plasma membrane ([Figure 4A](#fig4){ref-type="fig"}) but not in the cytosol ([Figure 4B](#fig4){ref-type="fig"}) or nucleus ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Thus, plasma membrane targeted EMBer could indeed be used to selectively inhibit the plasma membrane ERK activity. In cells expressing pmEMBer, we first observed an apparent change in cell morphology from primarily circular to primarily elliptical ([Figure 4C](#fig4){ref-type="fig"}). We quantified this morphological change by measuring the ratio of the minor to major axes of each cell, comparing between pmEMBer expressing cells and non-pmEMBer expressing cells ([Figure 4D](#fig4){ref-type="fig"}, Left panel). In cells without pmEMBer, 58% of imaged cells have a minor:major axes ratio greater than 0.8, indicating that the majority of cells were nearly perfectly round. Only \~8% of cells without pmEMBer had a ratio below 0.6. In contrast, 42% of pmEMBer expressing cells had a ratio below 0.6. This drastic change in cell morphology, which is dependent on pmEMBer expression at the plasma membrane, indicates that ERK activity near the membrane has an important role in controlling cell morphology.

![Inhibition of plasma membrane localized ERK activity alters cell morphology, EGF-induced protrusions, and Rac1 activation.\
(**A**) Effect on pmEKAR4 response to EGF in PC12 cells expressing a plasma membrane-targeted monobody EMBer7.1 (pmEMBer) ([@bib31]) which binds to ERK and dampens ERK activity (n = 36 cells, red curve). (**B**) Effect on cytoEKAR4 response to EGF in PC12 cells expressing pmEMBer (n = 37 cells, red curve) (**C**) Representative images of cell morphology and protrusion dynamics in response to EGF in PC12 cells with (bottom row) or without (top row) pmEMBer expression. (**D**) (Left-most panel) Major and minor axes of each cell was measured using ImageJ and the ratio of minor: major was calculated for each cell with and without pmEMBer expression. Kymographs generated from major axes of each cell plotting distance and time ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}) were used to quantitate protrusion length in µm and protrusion persistence in min. (Middle and right panels) (n = 103 pmEMBer, n = 57 +pmEMBer, \*\*\*p=0.0002, \*\*\*\*p\<0.0001) (**E**) Using Rac1-2G biosensor to measure Rac1 activity ([@bib40]), cells either expressing pmEMBer (red curve, n = 24 cells) or pm-mCherry (black curve, n = 19 cells) were treated with EGF. (**F**) Quantitation of Max Rac1-2G response to EGF. (p\<0.0001, Welch's t-test to correct for different variances.) See also [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}, [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}, [Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}.\
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In conjunction with the observed changes in morphology, we observed apparent changes in EGF-induced membrane protrusion dynamics. To quantitate these observations, we co-expressed either pmEMBer or plasma membrane targeted mCherry with LifeAct-Venus ([@bib14]) to visualize actin dynamics. In each of these conditions, cells were treated with EGF and imaged every 30 s for up to 45 min after stimulation. To quantitate the differences in protrusion dynamics, lines were drawn across the major axis of each cell and a kymograph was generated to quantitate the spatial and temporal aspects of protrusion dynamics ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). Under control conditions, EGF induced relatively short-lived, evenly distributed small protrusions ([Figure 4D](#fig4){ref-type="fig"}, middle, right panels). However, under conditions of selective plasma membrane inhibition of ERK activity near the plasma membrane, cells exhibited longer and polarized protrusion dynamics ([Figure 4D](#fig4){ref-type="fig"}, middle, right panels). Specifically, in normal conditions, 28% of cells had protrusions longer than 5 µm and the protrusions of 25% of these cells lasted for longer than 15 min. In contrast, in plasma mebrane ERK (pmERK)-inhibited conditions, 70% of cells had protrusions longer than 5 µm and 75% of pmERK-inhibited cells had protrusions lasting longer than 15 min.

As described earlier, there are known ERK substrates near the membrane that could have the observed effect on cell morphology and protrusions, such as WASP, FAK, among others ([@bib59]). Furthermore, it is well established that the Rho family of GTPases, Rac1 and RhoA, are significant players in cell protrusion and migration processes. Importantly, Rac1 is a known substrate for ERK, and EGF-induced Rac1 phosphorylation by ERK in COS-7 cells was shown to lead to inhibition of Rac1 and its removal from the plasma membrane ([@bib58]). Thus, we sought to examine how inhibition of plasma membrane ERK affected Rac1 and RhoA activity in PC12 cells.

In order to monitor Rac1 and RhoA activation, we took advantage of established single-chain Rac1 and RhoA biosensors: Rac1-2G ([@bib10]) and RhoA-DORA ([@bib60]). Rac1-2G consists of mTFP (variant of CFP) on the N-terminus, a circularly permutated variant of Venus, with the PAK effector binding domain in between the two fluorescent proteins and a full length Rac1 at the C-terminal end; upon Rac1 binding with GTP, the PAK effector domain will interact with Rac1-GTP, bringing the two fluorescent proteins into close proximity to increase FRET. The RhoA biosensor has a similar design, with a circularly permutated Rho-binding domain of PKN1 on the N-terminus, followed by cpVenus, a linker region, Cerulean, and then full-length RhoA. We expressed either of these biosensors in cells along with either plasma membrane targeted mCherry (control) or pmEMBer. Although we could not observe RhoA activity under either condition ([Figure 4---figure supplement 3C,D,E](#fig4s3){ref-type="fig"}), using Rac1-2G we did observe a robust 6.4 ± 0.7% increase in response to EGF (n = 19, control; n = 24, with pmEMBer) under pmERK-inhibited conditions but not under control conditions ([Figure 4E,F](#fig4){ref-type="fig"}), indicating endogenous pmERK inhibits Rac1 activation. This observation is consistent with previous reports in which ERK phosphorylation of Rac1 on T108 inhibits Rac1 and leads to relocalization of Rac1 away from the membrane ([@bib58]) and indicates that plasma membrane ERK activity inhibits Rac1, which could contribute to the regulation of membrane protrusion dynamics.

Discussion {#s3}
==========

Although ERK is ubiquitously utilized by a host of different cellular processes, the majority of studies on ERK focus on its primary role in proliferation and survival. Previous studies often focus on investigating the extent of ERK phosphorylation and its effect on transcription factors in the nucleus. However, ERK is known to have hundreds of substrates localized in different subcellular compartments and play key roles in differentiation, migration, and others ([@bib45]; [@bib59]; [@bib29]). Despite our knowledge of substrate localization, little is known about the regulation of ERK in specific subcellular compartments outside of the nucleus. This is largely due to the traditional method of using phospho-specific antibodies on whole lysates, which are equated, perhaps erroneously ([@bib23]; [@bib55]), with full activity, and may mask subpopulations of ERK amidst the majority population. While we know that temporal dynamics plays a major role in determining cellular processes resulting from an extracellular cue, we have been unable to critically assess whether an individual extracellular signal can induce distinct temporal dynamics among two or more different subcellular compartments.

In this study, we established the use of fluorescent, FRET-based biosensors to study the spatiotemporal dynamics of ERK activity by targeting the biosensors to specific subcellular regions, particularly the plasma membrane, cytosol, and nucleus. Using this technique, we discovered that EGF simultaneously activates at least three divergent sub-populations of ERK with unique temporal dynamics from each other: the cytosol ([Figure 1C](#fig1){ref-type="fig"}), the Plasma membrane ([Figure 1D](#fig1){ref-type="fig"}), and the nucleus ([Figure 1---figure supplement 3C](#fig1s3){ref-type="fig"}). Indeed, the nuclear EKAR4 response exhibits the most transient of the targeted EKAR4 biosensors, followed by cytoEKAR4, with the pmEKAR4 exhibiting an apparent persistent response ([Figure 1D,E](#fig1){ref-type="fig"}). By using a membrane-permeable ERK inhibitor, we confirmed that the sustained pmEKAR4 signal was a direct result of continued ERK phosphorylation of the biosensor and not because the biosensor was unable to be dephosphorylated by a lack of phosphatases near the membrane ([Figure 2A](#fig2){ref-type="fig"}). Additionally, we utilized subcellular fractionation and immunoblotting to confirm the presence of sustained ERK phosphorylation in the plasma membrane fraction ([Figure 2B,C](#fig2){ref-type="fig"}).

To delineate into the mechanism by which ERK activity at the membrane is activated, we examined the upstream GTPase responsible for ERK activation and discovered a noncanonical Rap1-mediated pathway. Past studies have linked Rap1 to ERK signaling because Rap1 is able to interact with and activate B-Raf ([@bib56]). However, this point has been controversial and it is not clear whether or not Rap1 actually activates ERK in a cellular environment, with studies giving disparate reports on whether EGF induces Rap1 activation in PC12 cells ([@bib63]; [@bib67]; [@bib20]; [@bib64]; [@bib1]; [@bib25]). These contradicting observations are likely due to the fact that the traditional biochemical method for measuring enzyme activation may not capture transient or specific subcellularly localized activation ([@bib63]). In this study, with the use of recently reported Rap1 biosensors ([Figure 3A--B](#fig3){ref-type="fig"}; [@bib40]) and our live-cell TIRF-based EGFP-RalGDS translocation assay ([Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}), we were able to show that, in PC12 cells, EGF does indeed activate Rap1 at the plasma membrane. Using Rap1GAP ([Figure 3C--F](#fig3){ref-type="fig"}), a dominant negative form of Rap1B ([Figure 3---figure supplement 5](#fig3s5){ref-type="fig"}), and the geranylgeranyl transferase I inhibitor ([Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}), combined with our plasma membrane ERK activity reporter, we further showed that Rap1 is critically involved in regulating plasma membrane ERK activity but does not appear to contribute to the Ras-dependent cytosolic or nuclear ERK activities, whereas Ras appears to primarily contribute to the initial, but not sustained, component of plasma membrane ERK activity ([Figure 3---figure supplement 6](#fig3s6){ref-type="fig"}). Future studies will test the involvement of Rap1 GEFs and B-Raf in Rap1-mediated plasma membrane ERK activation.

Furthermore, our study provides a striking example where an individual extracellular signal, such as EGF, can temporally regulate subcellular ERK populations to control distinct cellular processes. We showed that inhibition of membrane-localized ERK activity potentiates EGF-induced Rac1 activation and leads to enhanced membrane protrusion dynamics. These data suggest that EGF, in addition to inducing cell proliferation, also stimulates plasma membrane ERK activity to suppress Rac1 activity to prevent unwanted membrane protrusions and polarization. The latter effect likely requires the sustained ERK activity at the plasma membrane. It is tempting to speculate that the ERK-suppressed morphology and protrusions are related to PC12 cell differentiation, due to the qualitative resemblance of shape and protrusion dynamics for pmEMBer-expressing cells compared to cells shortly after NGF treatment ([@bib44]). Thus, spatial and temporal dynamics are intricately linked to encode specific signaling information and regulate distinct cellular processes that result from individual extracellular signals such as EGF. With the genetically targeted molecular tools for both visualization and manipulation of specific signaling events, our work also lays the foundation to enable future studies to further elucidate the mechanisms of regulation and functional roles of distinct subcellular populations of ERK.

Materials and methods {#s4}
=====================

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\             Designation                             Source or reference                                             Identifiers                                                    Additional\
  (species) or\                                                                                                                                                                                    information
  resource                                                                                                                                                                                         
  ------------------------- --------------------------------------- --------------------------------------------------------------- -------------------------------------------------------------- -------------------
  Chemical compound, drug   SCH772984                               selleckchem                                                     S7101                                                          

  Chemical compound, drug   U0126                                   Sigma                                                           U120                                                           

  Chemical compound, drug   Epidermal Growth\                       Sigma                                                           E9644                                                          
                            Factor (EGF)                                                                                                                                                           

  Antibody                  Anti-phosphoERK1/2 rabbit, polyclonal   Cell Signalling Technology                                      Cat\# 9102\                                                    (1:1000) dilution
                                                                                                                                    RRID:[AB_330744](https://scicrunch.org/resolver/AB_330744)     

  Antibody                  Anti-ERK1/2 rabbit, polyclonal          Cell Signalling Technology                                      Cat\# 9101\                                                    (1:1000) dilution
                                                                                                                                    RRID:[AB_331646](https://scicrunch.org/resolver/AB_331646)     

  Commercial assay or Kit   Lipofectamine-2000                      Invitrogen                                                      11668019                                                       

  Recombinant\              pCDNA3 EKAR-EV                          PMID:[21976697](https://www.ncbi.nlm.nih.gov/pubmed/21976697)                                                                  
  DNA Reagent                                                                                                                                                                                      

  Recombinant\              pTriEx4 Rap1A-FLARE                     PMID:[31444239](https://www.ncbi.nlm.nih.gov/pubmed/31444239)                                                                  
  DNA Reagent                                                                                                                                                                                      

  Recombinant\              pTriEx4 Rap1B-FLARE                     PMID:[31444239](https://www.ncbi.nlm.nih.gov/pubmed/31444239)                                                                  
  DNA Reagent                                                                                                                                                                                      

  Recombinant\              pcDNA3 Flag-Rap1GAP                     PMID:[23946483](https://www.ncbi.nlm.nih.gov/pubmed/23946483)                                                                  
  DNA Reagent                                                                                                                                                                                      

  Recombinant\              pcDNA3 EMBer7.1                         PMID:[23227961](https://www.ncbi.nlm.nih.gov/pubmed/23227961)                                                                  
  DNA Reagent                                                                                                                                                                                      

  Cell Line\                PC-12                                   PMID:[1065897](https://www.ncbi.nlm.nih.gov/pubmed/1065897)     RRID:[CVCL_0481](https://scicrunch.org/resolver/CVCL_0481)     
  (*Rattus norvegicus*)                                                                                                                                                                            

  Cell Line\                HEK293-T                                                                                                RRID:[CVCL_0063](https://scicrunch.org/resolver/CVCL_0063)     
  (*Homo sapiens*)                                                                                                                                                                                 

  Software, algorithm       FIJI                                                                                                    RRID:[SCR_014294](https://scicrunch.org/resolver/SCR_014294)   

  Software, algorithm       MetaFluor                                                                                               RRID:[SCR_002285](https://scicrunch.org/resolver/SCR_002285)   

  Software, algorithm       GraphPad Prism                                                                                          RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798)   
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Reagents {#s4-1}
--------

ERK inhibitor SCH772984 was obtained from Sellek chemicals. ERK1/2 (Cell Signaling Technology Cat\# 9102, RRID:[AB_330744](https://scicrunch.org/resolver/AB_330744)) and phospho-ERK1/2 (Cell Signaling Technology Cat\# 9101, RRID:[AB_331646](https://scicrunch.org/resolver/AB_331646)) antibodies were from CST. Epidermal growth factor (EGF) was from Sigma-Aldrich.

Plasmid generation and molecular biology {#s4-2}
----------------------------------------

EKAR-EV was kindly provided by Michiyuki Matsuda. To generate EKAR4, locations of ECFP and Ypet were swapped by restriction digest. Subcellular targeting sequences were subcloned onto the C-terminal end of EKAR4 in between the EcoRI and XbaI restriction sites. The sequences include: for nuclear export sequence (5\'-GAATTCCTGCCCCCCCTGGAGCGCCTGACCCTGTAA-3\'), for nuclear import sequence (5\'-CCAAAAAAGAAGAGAaaggtggaagacgca-3\'), and for plasma membrane localization (5\'-AAGAAGAAGAAGAAGAGCAAGACCAAGTGCGTGATCATGTAA-3\'.) The corresponding peptide sequences are LPPLERLTL, PKKKRKVEDA, and KKKKKSKTKCVIM, respectively. The full annotated sequence for cytoEKAR4 is included as [Supplementary file 1](#supp1){ref-type="supplementary-material"} and the sequence for pmEKAR4 is included as [Supplementary file 2](#supp2){ref-type="supplementary-material"}. Flag-Rap1GAP, Rap1A-N17 and Rap1B-N17, and EGFP-RalGDS was kindly provided by Philip Stork. Flag-Rap1GAP was PCR-purified out of the provided plasmid using the forward primer (5\'- gggatctgtacgacgatgacgataagGATCCCATGATTGAGAAGATGCAGGGAAGCAGGA-3') and reverse primer (5'- ACAGCCCAGCTGGGGCATGCCCTTGCTCACCATGTCGACAAAGGTACC-3'). The PCR product was then subcloned using Gibson assembly into pcDNA3 containing mCherry using the following primers: (5'- TCTGAGCAGCACATGCCCCAGCTGGGCTGTGGTACCTTTGTCGACATGGTGAGCAAGGGC-3'), (5'-cttatcgtcatcgtcgtacagatcccgacc-3'), (5'- ATTGCATCGCATTGTCTGAGTAGGTG-3'), and (5'-CGCTCTTTCTGGTCATCCAGGCGAA-3'). Sequences for ERK monobody binders kindly provided by Sheldon Park. EMBer7.1 was subcloned into pRset containing the mCherry fluorescent protein between the BamHI and SacI sites such that EMBer7.1 would be tagged with mCherry on its C-terminal end. EMBer7.1-mCherry was then subcloned into pcDNA three after silent mutation of the internal BamHI site within EMBer7.1 between the BamHI and EcoRI sites. The plasma membrane targeting sequence was inserted on the C-terminal end of mCherry between the EcoRI and XbaI sites; the subsequent product was termed pmEMBer7.1. Creation of LifeAct-Venus was previously reported ([@bib14]). Rac1-2g in pTriEx4 was a gift from Oliver Pertz (Addgene plasmid \# 66110), and Dora-RhoA was kindly provided by Yi Wu (University of Connecticut). Rap1A-FLARE and Rap1B-FLARE were kindly provided by Klaus Hahn (UNC-Chapel Hill).

Cell culture and transfection {#s4-3}
-----------------------------

PC12 cells were grown in Dulbecco modified Eagle medium (DMEM) cell culture medium supplemented with 10% fetal bovine serum (FBS) and 5% donor horse serum (DHS) at 37°C with 5% CO~2~. HEK293T cells were maintained using Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. Cells were plated onto 35 mm glass-bottom dishes for imaging, 60 mm culture dishes for immunoblotting studies, or 15 cm culture dishes for fractionation studies. When necessary, cells were transfected at 50% to 60% confluence via Lipofectamine 2000 (Invitrogen) for 24--48 hr prior to imaging. Cells were recovered from frozen stocks, maintained for limited passages and screened regularly to confirm the absence of mycoplasma contamination using Hoechst staining.

Cellular fractionation and immunoblotting {#s4-4}
-----------------------------------------

PC12 cells were washed 2x with ice cold 1X PBS and harvested in 1X PBS. Cells were centrifuged for 5 min at 5000 RPM at 4 °C, resuspended in 250 µL of 1X hypotonic lysis buffer (20 mM HEPES, pH 7.4, 10 mM NaCl, 3 mM MgCl2, Roche protease cocktail inhibitors and 1 mM PMSF), and incubated from 30 min to 1 hr to allow for cell lysis. Cells were passed through a 27 ½ G needle 10x to maximize lysis and centrifuged 2x at 5000 RPM to pellet nucleus. BCA quantification was performed and protein levels were normalized to the lowest protein concentration (2--2.5 mg/mL). Pellets were washed 2x and combined in 250 µL of hypotonic buffer. Supernatant was ultracentrifuged at 52,000 RPM for 1 hr at 4 °C. Supernatant was saved as the cytoplasmic fraction. Membrane pellet was resuspended in 250 µL of hypotonic buffer and passed sample through a 27 ½ G syringe 10x, and centrifuged for 45 min at 52,000 RPM at 4 °C. Supernatant was combined with the cytoplasmic for a total of 500 µL. Membrane pellet was resuspended in 250 µL of hypotonic buffer, combined with the nuclear fractions with membrane fractions and solubilized membrane by adding NP-40 at a final concentration of 0.5%. Lysates were centrifuged 2x at 5000 RPM to pellet nucleus where your supernatant is the membrane fraction. The pellets were combined in 500 mL of hypotonic and sonicated to solubilize. Samples were prepared with LSB+DTT and assessed via SDS-PAGE. 9% gels were resolved and transferred to PVDF membranes. Membranes were blocked for 1 hr in 4% BSA and probed for rbαNa^+^/K ATPase^+^ (1:1000), msαP84 (1:2000), msαGAPDH (1:50,000), p-ERK (1:1000) and total ERK (1:1000). Phospho-ERK was normalized to total ERK within its corresponding fraction. Fraction of maximal response was obtained and analyzed repeats in Prism via Two-way ANOVA.

Cellular imaging and analysis {#s4-5}
-----------------------------

### Epifluorescence imaging {#s4-5-1}

Cells were washed twice with Hank's balanced salt solution (HBSS, Gibco) and incubated at 37°C for 30 min prior to imaging. Cells were subsequently imaged in HBSS in the dark at 37°C. Epidermal growth factor (EGF; Sigma-Aldrich) and SCH772984 (Selleck) were added as indicated; a minimum of three biological replicates (individual dish) were collected for each condition. Images were acquired on a Zeiss AxioObserver Z1 microscope (Carl Zeiss) equipped with a 40×/1.3NA objective and a Photometrics Evolve 512 EMCCD (Photometrics) controlled by METAFLUOR 7.7 software (Molecular Devices). Dual cyan/yellow emission ratio imaging was performed using a 420DF20 excitation filter, a 450DRLP dichroic mirror and two emission filters (475DF40 for CFP and 535DF25 for YFP). All filter sets were alternated by a Lambda 10--2 filter-changer (Sutter Instruments). Exposure times ranged between 50 and 500 ms, with the EM gain set from 10 to 50, and images were acquired every 30 s. Raw fluorescence images were corrected by subtracting the background fluorescence intensity of a cell-free region from the emission intensities of biosensor-expressing cells. Yellow/cyan emission ratios were then calculated at each time point. The resulting time courses were normalized by dividing the ratio at each time point by the basal value at time zero (R/R0), which was defined as the time point immediately preceding drug addition. Maximum ratio (ΔR/R) changes were calculated as (Rmax−Rmin)/Rmin, where Rmax and Rmin are the maximum and minimum ratio value recorded after stimulation, respectively. Metric for sustained/transient comparisons was calculated as a ratio of remaining C/Y emission ratio 40 min after EGF stimulation to the maximum ratio response (R~40~-R~0~)/(R~max~-R~0~). Where R~40~ is the ratio at 40 min post-EGF treatment, R~0~ is the point preceding EGF stimulation, and R~max~ is the maximum ratio value recorded after stimulation. Graphs were plotted using GraphPad Prism 7 (GraphPad Software). Sample size reported as number of individual cells.

### Morphology and protrusion analysis {#s4-5-2}

Morphology was measured using ImageJ software to measure the distance, in microns, of the major and minor axes of each cell, and the ratio of the minor:major axes was compared between cells with versus without pmEMBer expression. Protrusion dynamics was measured using ImageJ software by creating a line across the major axis of each cell, and subsequently creating a kymograph from the stack of time course images. For the kymograph, the x-axis indicated distance (microns) and the y-axis indicated time (30 s per pixel). Using the kymographs, length in distance and time of each protrusion was measured and compared between conditions ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}).

### Total internal reflection microscopy (TIRF) {#s4-5-3}

Images were acquired on an Olympus IX-71 inverted microscope under a 150 × objective. An optical system with a 488 and 561 nm solid-state sapphire, coherent excitation laser and an EMCCD camera (iXon DU897E, Andor Technology) was used to examine the samples (emission, ZET488/561 m, Chroma Technology). Images in green (488 nm) and red (561 nm) channels were taken every 30 s before and after 100 ng/ml EGF stimulation. Resulting time course images were analyzed using ImageJ software. Intensity of each cell was measured throughout time course, ratio of GFP/RFP was taken to account for cell spreading that sometimes occurs after EGF treatment.

### Statistical analysis {#s4-5-4}

Statistics were calculated using Graphpad Prism seven software. When comparing average metrics of single cell curves, outliers were identified using ROUT with Q + 1%. Reported average is the mean ± SEM. Experiments comparing multiple conditions were compared were analyzed using Ordinary one-way ANOVA with multiple comparisons. Situations where only two conditions were compared were analyzed by an unpaired t-test, with Welch\'s correction if variances were shown to be different between the conditions. Statistical significance was assessed using p\<0.05 as a cutoff value. In combining single cell data, cells with clear unusual behavior (apoptotic blebbing) were cut from analysis, along with cells with extremely high or low start ratios or unusually bright or dim fluorescence (determined individually per condition by calculating Pearson\'s correlation coefficient between response metrics and Ratio or fluorescent starting conditions. This analysis was done to remove cells from analysis in which extremely high or low expression of the biosensor affected cell behavior; cells were cut from each condition until Pearson\'s correlation coefficient was below 0.5.
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**Acceptance summary:**

This study examines the temporal and spatial dynamics of ERK signaling using a newly developed sensor. The authors demonstrate that cell surface signaling to ERK is mediated initially by both Ras and Rap pathways, but long-term ERK activation is mediated by the Rap pathway. This finding provides novel insight into ERK signaling dynamics and clarifies the relative roles of the Ras and Rap pathways.

**Decision letter after peer review:**

\[Editors' note: the authors submitted for reconsideration following the decision after peer review. What follows is the decision letter after the first round of review.\]

Thank you for submitting your work entitled \"Signaling diversity enabled by Rap1-regulated plasma membrane ERK with distinct temporal dynamics\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Senior Editor. The reviewers have opted to remain anonymous.

Our decision has been reached after consultation among the reviewers. Based on these discussions and the individual reviews below, the reviewers concluded that revision of your manuscript would require more than 2 months, and thus we cannot formally invite a revised version according to *eLife* policy. Nevertheless, the reviewers remain interested in your study and are willing to consider a new version of this manuscript that addresses the points raised during the review.

This manuscript describes a new probe for ERK activity (EKAR4) that is employed to probe ERK signaling in live cells. A focus of the analysis is a demonstration that cell surface ERK activity is dependent upon the Rap1 signaling pathway. These are elegant and interesting studies. However, further characterization of EKAR4 was requested by the reviewers and additional data to support the conclusions concerning the role of Rap1 are required. These concerns are elaborated in the appended reviews.

Reviewer \#1:

This is an interesting study that describes the use of an improved biosensor for ERK activity (EKAR4) to investigate the spatiotemporal dynamics of ERK activity in response to treatment of PC12 cells with EGF. Many of the observations do not break new ground. However, the analysis of the role of Rap1 in cell surface activation of ERK does contribute to an unresolved area of previous research. The authors present data indicating the cell surface ERK activity is sustained and that this depends on Rap1.

The authors show that Rap1 is activated by EGF and that both RapGAP and dnRap1 suppresses cell surface activation of ERK. The function of cell surface ERK activation was probed using a targeted ERK monobody to demonstrate a role in membrane protrusion that may be mediated by a Rac1-dependent process. The analysis presented uses elegant optical probes and is interesting. However, the depth of mechanistic insight is limited -- thus is a problem for a controversial area of research. For example, a caveat on the interpretation of the RapGAP and dnRap1 studies is that the transfection protocol may cause long-term changes in EGFR signaling due to trafficking or some other EGFR signaling property. It is therefore not certain that Rap1 mediates the effects of EGF on cell surface ERK activity rather than some indirect action of Rap1 on EGFR signaling. Control studies are needed. First, does blocking the Ras pathway prevent cell surface ERK activation? Presumably, if Rap1 (and not Ras) is required for cell surface ERK activation, then blocking Ras would not alter cell surface ERK activation. Second, does acute Rap1-deficiency prevent cell surface ERK activation -- for example using induced Rap1 protein degradation. These studies are required to strengthen the conclusions of the current study and are important because of the existing controversy in this field.

Reviewer \#2:

General assessment of work:

This manuscript reports a new genetically encoded FRET sensor for ERK, named EKAR4, which has enhanced dynamic range compared to previous EKAR versions. The EKAR4 construct targeted to the plasma membrane is used to reveal novel evidence for sustained activation of membrane-localized ERK. The sensor is used in combination with inhibitors of Rap1 (Rap1-GAP and DN-Rap1) to address a previous claim that Rap1 is needed for ERK activation, which has been controversial and difficult to corroborate. The results show convincingly that plasma membrane associated ERK is partially dependent on Rap1-GTP. A plasma membrane targeted ERK monobody (EMBer) is used to demonstrate the importance of plasma membrane ERK on cell morphology and membrane protrusions.

This manuscript represents an important contribution to the signaling field, by describing a new probe for ERK signaling and using it to address long held ambiguities about the activation and function of plasma membrane associated kinase. The experiments are carefully done and the results will be of broad interest.

A number of points are raised to improve accuracy and clarity.

Detailed comments:

1\) Figure 1---figure supplement 1, Results paragraph one. It is unclear how the figure shows a 74.5% increase in Y/C emission ratio. Needed is a panel showing the direct comparison of EKAR4 against the previous generation EKARs, to document performance of the new sensor.

2\) Figure 2B,C. The Western blot in panel B looks as if phosphoERK at the membrane nearly returns to baseline after 40 min, while phosphoERK in the cytosol remains higher than baseline at 40 min. This seems inconsistent with the quantitative data in panel C.

3\) Figure 3---figure supplement 2 panel F. The experiments showing that Rap1GAP does not affect cytoEKAR (EKAR4-NES?) were averaged from n=15, whereas pmEKAR experiments were averaged from n=40. Data for pmEKAR with Rap1GAP showed a wide range of responses, where many time courses overlapped those of control. Concievably cytoEKAR might also show the same, if assayed to the same depth. Alternatively, the Rap1BN17 experiments should be performed with EKAR4-NES to confirm that the cytoplasmic sensor is unresponsive to Rap1 inhibition.

Reviewer \#3:

Keyes et al. describe a refinement of the EKAR genetically encoded biosensor for Extracellular regulated kinase (ERK) activity. Using similar technology that was used to engineer the original biosensor, the authors have improved sensitivity as evidenced by a 74 % increase in the Y/C emission ratio. More direct comparison to conventional methods of evaluating ERK activation should be also included. While there is no doubt that the development of this new reporter is valuable, the utilization of EKAR4 in this study does not reveal any substantial biological advances.

1\) Experiments in Figure 1 suggest that the signal to noise ratio of the membrane associated EKAR4 is less than cytoplasmic. Control experiments need to be included to ensure that the sustained activity metric presented in Figure 1E is really significant. Cytoplasm is spelt wrong in the title of Figure 1C.

2\) Additional drug experiments with MEK inhibitors should be added to the data in Figure 2A. Targeting this upstream kinase in the RAF-MEK-ERK pathway is a more standard method of pathway inhibition. These experiments could be used to further justify the development of another ERAR and establish if there are any MEK independent effects.

3\) The usage of multiple fluorescent biosensors to detect events upstream ERK signaling such as Rap 1 activations makes this work harder to follow. Also, can the authors show that activation of Eapc1 is involved in this process by treating with selective cAMP analog activators.

4\) It is stated in the discussion \"we found that ERK activation in the nucleus was transient, slightly more sustained in the cytoplasm and drastically more sustained near the plasma membrane\". This seems a rather obvious statement since the agonist used to stimulate ERK activation is delivered from the plasma membrane. The authors need to provide more compelling evidence and rational for this conclusion.

\[Editors' note: further revisions were suggested prior to acceptance, as described below.\]

Thank you for submitting your article \"Signaling Diversity Enabled by Rap1-Regulated Plasma Membrane ERK with Distinct Temporal Dynamics\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Philip Cole as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, we are asking editors to accept without delay manuscripts, like yours, that they judge can stand as *eLife* papers without additional data, even if they feel that they would make the manuscript stronger. Thus the revisions requested below only address clarity and presentation.

This manuscript represents an important contribution to the signaling field, by describing a new probe for ERK signaling and using it to address long-held ambiguities about the activation and function of plasma membrane associated kinase. The experiments are carefully done and the results will be of broad interest. The responses to the reviews were thorough and comprehensive. The findings of the revised manuscript are significant and at a level appropriate for this journal.

Two minor issues should be addressed by the authors before the paper is published.

1\) The new supplemental data presented in Figure 3---figure supplement 6 appears to be noisy (particularly figure D). It might help interpretation if the analyses used the same scale for the quantification of the Y/C ratio as figure C. There is a similar issue, but to a lesser extent, with Figure 3---figure supplement 6 (A and C).

2\) New immunoblot data presented in Figure 1---figure supplement 5. Please confirm in the figure legend that this figure panel represents the same extract examined in separate blots for ERK and pERK and that this is why two tubulin loading controls are presented. Otherwise, please explain.
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Author response

\[Editors' note: the authors resubmitted a revised version of the paper for consideration. What follows is the authors' response to the first round of review.\]

> Reviewer \#1:
>
> This is an interesting study that describes the use of an improved biosensor for ERK activity (EKAR4) to investigate the spatiotemporal dynamics of ERK activity in response to treatment of PC12 cells with EGF. Many of the observations do not break new ground. However, the analysis of the role of Rap1 in cell surface activation of ERK does contribute to an unresolved area of previous research. The authors present data indicating the cell surface ERK activity is sustained and that this depends on Rap1.
>
> The authors show that Rap1 is activated by EGF and that both RapGAP and dnRap1 suppresses cell surface activation of ERK. The function of cell surface ERK activation was probed using a targeted ERK monobody to demonstrate a role in membrane protrusion that may be mediated by a Rac1-dependent process. The analysis presented uses elegant optical probes and is interesting. However, the depth of mechanistic insight is limited -- thus is a problem for a controversial area of research. For example, a caveat on the interpretation of the RapGAP and dnRap1 studies is that the transfection protocol may cause long-term changes in EGFR signaling due to trafficking or some other EGFR signaling property. It is therefore not certain that Rap1 mediates the effects of EGF on cell surface ERK activity rather than some indirect action of Rap1 on EGFR signaling. Control studies are needed. First, does blocking the Ras pathway prevent cell surface ERK activation? Presumably, if Rap1 (and not Ras) is required for cell surface ERK activation, then blocking Ras would not alter cell surface ERK activation. Second, does acute Rap1-deficiency prevent cell surface ERK activation -- for example using induced Rap1 protein degradation. These studies are required to strengthen the conclusions of the current study and are important because of the existing controversy in this field.

We thank reviewer 1 for the detailed and thoughtful comments. We have performed additional experiments, which have led to a more complete understanding of the roles of Ras and Rap1 in regulating ERK.

As suggested by the reviewers, we performed additional experiments to test how inhibition of Ras, via use of HRas-17N dominant negative overexpression, effects ERK responses. We found Ras inhibition affects both pmEKAR4 and cytoEKAR4 responses. As shown in Figure 3---figure supplement 6, HRasN17 expression completely abolishes cytosolic ERK response and decreased the plasma membrane ERK response by 57% at normal peak signal (\~10-15 min) but 0% at 40 minutes post EGF, suggesting that Ras is not required for the sustained ERK response at the plasma membrane but required for regulating both cytosolic ERK and the initial activation of plasma membrane ERK. Indeed, as shown in Figure 3C, Rap1GAP expression does not completely abrogate pmEKAR4 response. Given that expression of Rap1GAP was shown to abolish Rap1 activation (Figure 3A and 3B), this data, combined with Figure 3 and Figure 3---figure supplement 6, suggests that both Rap1 and Ras contribute to the plasma membrane ERK response but Rap1, not Ras, is responsible for plasma membrane ERK activity at later time points. We discuss these results in paragraph two of subsection "Rap1 GTPase significantly contributes to plasma membrane ERK activity" and Discussion paragraph three.

We tested different approaches to achieve acute inhibition of Rap1. We attempted to create a cell line where we could more acutely inhibit the Rap1 pathway using either a targeted degradation system or a cell line in which we could induce the overexpression of Rap1GAP. However, we were unsuccessful in creating a stable PC12 cell line expressing either of these constructs due to significant cell death after viral transduction. We thus utilized GGTI-298, a geranylgeranyltransferase I inhibitor that has been used to inhibit the processing and thus action of Rap1 (Chenette and Der, 2011; Ke et al., 2019; McGuire et al., 1996). Because Rap1, but not Ras, is geranylgeranylated, GGTI-298 is used as a semi-specific inhibitor for Rap1 (Chenette and Der, 2011). We found that 30 μM pretreatment of GGTI-298 150 minutes before EGF treatment effectively abrogated Rap1 signaling as measured using the Rap1A biosensor (Figure 3---figure supplement 3A, C, E) and had a dramatic effect on pmEKAR4 response (Figure 3---figure supplement 3B, D, F). While we acknowledge that GGTI-298 could have off target effects, we noted that 150-min pretreatment with GGTI-298 leads to a similar pmEKAR4 response as Rap1GAP overexpression and included this data as a supporting piece of evidence for the role of Rap1 in regulating plasma membrane ERK. We include discussion using GGTI-298 in subsection "Rap1 GTPase significantly contributes to plasma membrane ERK activity".

> Reviewer \#2:
>
> General assessment of work:
>
> This manuscript reports a new genetically encoded FRET sensor for ERK, named EKAR4, which has enhanced dynamic range compared to previous EKAR versions. The EKAR4 construct targeted to the plasma membrane is used to reveal novel evidence for sustained activation of membrane-localized ERK. The sensor is used in combination with inhibitors of Rap1 (Rap1-GAP and DN-Rap1) to address a previous claim that Rap1 is needed for ERK activation, which has been controversial and difficult to corroborate. The results show convincingly that plasma membrane associated ERK is partially dependent on Rap1-GTP. A plasma membrane targeted ERK monobody (EMBer) is used to demonstrate the importance of plasma membrane ERK on cell morphology and membrane protrusions.
>
> This manuscript represents an important contribution to the signaling field, by describing a new probe for ERK signaling and using it to address long held ambiguities about the activation and function of plasma membrane associated kinase. The experiments are carefully done and the results will be of broad interest.
>
> A number of points are raised to improve accuracy and clarity.
>
> Detailed comments:
>
> 1\) Figure 1---figure supplement 1, . Results paragraph one. It is unclear how the figure shows a 74.5% increase in Y/C emission ratio. Needed is a panel showing the direct comparison of EKAR4 against the previous generation EKARs, to document performance of the new sensor.

Per reviewer 2's request, we obtained EKAR-EV (Komatsu et al., 2011), EKAR2G1, (Fritz et al., 2013), and EKAR 3 (Sparta et al., 2015), and the yet unpublished EKAR3.5 from John Albeck (UC Davis), which is an improved version of EKAR3. We used HEK-293T cells to directly compare the dynamic ranges of these different EKARs. We found that the dynamic range of EKAR4 is significantly improved over previous generations of EKAR ([Author response image 1](#sa2fig1){ref-type="fig"}). We were unable to express EKAR 3, and because EKAR3.5 is yet unpublished, we did not include it in Figure 1---figure supplement 1, which shows the significant improvement in dynamic range of EKAR4 over EKAR-EV and EKAR2G1. We discuss these results in paragraph one of the Results section.

![EKAR4 exhibits improved dynamic range over existing EKAR constructs.\
A) Average line traces of EKAR responses to EGF in Hek-293T cells. B) Quantification of max amplitude responses from each respective EKAR. (\*\*\*\* p\<0.0001 using one-way ordinary ANOVA, n=20 EKAR-EV and EKAR2G1, n=18 EKAR3.5, n=29 EKAR4.).](elife-57410-resp-fig1){#sa2fig1}

> 2\) Figure 2B,C. The Western blot in panel B looks as if phosphoERK at the membrane nearly returns to baseline after 40 min, while phosphoERK in the cytosol remains higher than baseline at 40 min. This seems inconsistent with the quantitative data in panel C.

Per reviewer 1 and 2's concerns, we reviewed and repeated the fractionation and western blots and replaced the previous representative image with a replicate whose image is more representative of the quantified data.

> 3\) Figure 3---figure supplement 2 panel F. The experiments showing that Rap1GAP does not affect cytoEKAR (EKAR4-NES?) were averaged from n=15, whereas pmEKAR experiments were averaged from n=40. Data for pmEKAR with Rap1GAP showed a wide range of responses, where many time courses overlapped those of control. Concievably cytoEKAR might also show the same, if assayed to the same depth. Alternatively, the Rap1BN17 experiments should be performed with EKAR4-NES to confirm that the cytoplasmic sensor is unresponsive to Rap1 inhibition.

We are thankful for reviewer 2's thoughtful consideration of replicate numbers and the variation in the pmEKAR response in Figure 3---figure supplement 2E. We have repeated the cytoEKAR4 experiment with Rap1GAP expression to reach the same N number (n=40) and concluded that Rap1GAP has no significant effect on cytosolic EKAR response. Changes are reflected in Figure 3 D, F, and Figure 3---figure supplement 2F. (Note the change in Figure supplement number due to addition of the diagram figure as Figure 3---figure supplement 1).

> Reviewer \#3:
>
> Keyes et al. describe a refinement of the EKAR genetically encoded biosensor for Extracellular regulated kinase (ERK) activity. Using similar technology that was used to engineer the original biosensor, the authors have improved sensitivity as evidenced by a 74 % increase in the Y/C emission ratio. More direct comparison to conventional methods of evaluating ERK activation should be also included. While there is no doubt that the development of this new reporter is valuable, the utilization of EKAR4 in this study does not reveal any substantial biological advances.

Per reviewer request, we included immunoblot time course data in Figure 1---figure supplement 5. The immunoblots were from whole cell lysate, which is the more traditional method of measuring ERK activation.

In this time course, we observe a dramatic increase in phosphorylated ERK 7.5 minutes after EGF treatment, followed by a dramatic decrease by 15 minutes. It is interesting that after 15 minutes we see a slight increase in phospho-ERK at the 30- and 40-minute time points. The activation profile is broadly similar to the EKAR response. The decrease in phospho-ERK is faster than the EKAR signal likely because the EKAR biosensor signal dynamics is dependent on both ERK and phosphatase activities. However, it is important to note that measurements of ERK phosphorylation is an indirect measure of ERK activity and that the phospho-ERK immunoblot is a measure of phosphorylated ERK from all compartments of all cells. We include discussion of this in the manuscript in paragraph two of the Results section.

> 1\) Experiments in Figure 1 suggest that the signal to noise ratio of the membrane associated EKAR4 is less than cytoplasmic. Control experiments need to be included to ensure that the sustained activity metric presented in Figure 1E is really significant. Cytoplasm is spelt wrong in the title of Figure 1C.

It is true that pmEKAR4 has a lower dynamic range than cytoEKAR4. We thus included a new supplemental figure (Figure 1---figure supplement 4) in which we show no significant correlation between amplitude and SAM40, indicating that the lower amplitude in pmEKAR does not affect the SAM40 measurement.

We also fixed the spelling in Figure 1C.

> 2\) Additional drug experiments with MEK inhibitors should be added to the data in Figure 2A. Targeting this upstream kinase in the RAF-MEK-ERK pathway is a more standard method of pathway inhibition. These experiments could be used to further justify the development of another ERAR and establish if there are any MEK independent effects.

We chose to use an ERK inhibitor to determine if ERK is still actively phosphorylating pmEKAR4 at a given time. But indeed MEK inhibition is a more widely used method to inhibit the pathway. Per reviewer request, we have included data using MEK inhibitor U0126 as a supplemental figure (Figure 2---figure supplement 2) and including brief discussion of the results in paragraph four of the Results section.

> 3\) The usage of multiple fluorescent biosensors to detect events upstream ERK signaling such as Rap 1 activations makes this work harder to follow. Also, can the authors show that activation of Eapc1 is involved in this process by treating with selective cAMP analog activators.

To make it easier to follow, we have now included a supplementary figure (Figure 3---figure supplement 1 to illustrate the pathway and the various biosensors and inhibitors used in this study, referred to in subsection "Rap1 GTPase significantly contributes to plasma membrane ERK activity".

We appreciate reviewer 3's question concerning the involvement of Epac. Based on the literature (Liu et al., 2010; Obara et al., 2007; Wang et al., 2006), we believe that C3G is a more likely candidate than Epac for the EGF-induced activation of Rap1 in this system owing to the localization of Epac away from the membrane. However, investigation of the mechanism of Rap1 activation, which involves specific inhibition of different GEFs, we feel, is beyond the scope of this current manuscript and more appropriately aligned with ongoing follow up studies, which we mention in paragraph three of the Discussion.

> 4\) It is stated in the discussion \"we found that ERK activation in the nucleus was transient, slightly more sustained in the cytoplasm and drastically more sustained near the plasma membrane\". This seems a rather obvious statement since the agonist used to stimulate ERK activation is delivered from the plasma membrane. The authors need to provide more compelling evidence and rational for this conclusion.

To address reviewer 3's concern, we modified the wording in paragraph two of the Discussion to more accurately reflect our observations on the apparent transience or persistence of ERK activity using the targeted EKAR4 biosensors. We also slightly modified the wording in the same paragraph to emphasize how experiments in Figure 2 support the stated conclusion that ERK phosphorylation and activity is sustained near the plasma membrane.

\[Editors' note: what follows is the authors' response to the second round of review.\]

> Two minor issues should be addressed by the authors before the paper is published.
>
> 1\) The new supplemental data presented in Figure 3---figure supplement 6 appears to be noisy (particularly figure D). It might help interpretation if the analyses used the same scale for the quantification of the Y/C ratio as figure C. There is a similar issue, but to a lesser extent, with Figure 3---figure supplement 6 (A and C).

We modified Figure 3---figure supplement 6 such that Panels A and B have the same scale on the Y-axis, and Panels C and D have the same Y-axis scale as each other.

> 2\) New immunoblot data presented in Figure 1---figure supplement 5. Please confirm in the figure legend that this figure panel represents the same extract examined in separate blots for ERK and pERK and that this is why two tubulin loading controls are presented. Otherwise, please explain.

We thank the reviewers and editors for aiding in clarifying this supplemental figure. There were two sets of immunoblots, pERK1/2 + tubulin (top) and ERK1/2 + tubulin (bottom) that are from separately run gels. As indicated in the revised figure, the columns represent the two biological replicates, and the samples in a given column are from the same set of lysates. Each tubulin blot is a loading control for the associated ERK immunoblot. We clarified this in the figure legend and modified the figure itself to clarify the reason for the two tubulin blots.

[^1]: IBM, Global Business Services, New York, United States.
